SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting “FOR” Pending Merger with Standard BioTools
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools
BOULDER, Colo., Jan. 2, 2024 /PRNewswire/ — SomaLogic, Inc. (Nasdaq: SLGC) (“the Company”), a leader in proteomics technology, today sent the following open letter to stockholders urging them to vote “FOR” the value maximizing transaction with Standard BioTools.
Related news for (SLGC)
- SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
- Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools
- Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools
- Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures